Skip to main content
Top
Published in: Diabetologia 7/2004

01-07-2004 | Commentary

Does WHI tell us how to prevent diabetes?

Author: E. R. Seaquist

Published in: Diabetologia | Issue 7/2004

Login to get access

Excerpt

Diabetes is occurring in epidemic proportions around the globe. Using the WHO global database, King and colleagues have estimated that the number of adults with diabetes will increase from 135 million in 1995 to 300 million in 2025, with a predicted world diabetes prevalence of 5.4% [1]. Most of these future cases are expected to occur in the developing world, but the prevalence of self-reported diabetes in the United States has already increased, from 4.9% in 1990 to 7.3% in 2000 [2]. Women are more likely to develop diabetes [2], and since women with diabetes have not experienced the same reduction in cardiovascular outcomes as men with diabetes in recent years [3], it can be a particularly devastating disease for them. …
Literature
1.
go back to reference King H, Aubert RE, Herman WH (1998) Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care 21:1414–1431CrossRefPubMed King H, Aubert RE, Herman WH (1998) Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care 21:1414–1431CrossRefPubMed
2.
go back to reference Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP (2001) The continuing epidemics of obesity and diabetes in the United States. JAMA 286:1195–1200CrossRefPubMed Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP (2001) The continuing epidemics of obesity and diabetes in the United States. JAMA 286:1195–1200CrossRefPubMed
3.
go back to reference Gu K, Cowie CC, Harris MI (1999) Diabetes and decline in heart disease mortality in US adults. JAMA 281:1291–1297CrossRefPubMed Gu K, Cowie CC, Harris MI (1999) Diabetes and decline in heart disease mortality in US adults. JAMA 281:1291–1297CrossRefPubMed
4.
go back to reference Knowler WC, Barrett-Connor E, Fowler SE et al. (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403CrossRefPubMed Knowler WC, Barrett-Connor E, Fowler SE et al. (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403CrossRefPubMed
5.
go back to reference Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072–2077CrossRefPubMed Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072–2077CrossRefPubMed
6.
go back to reference Buchanan TA, Xiang AH, Peters RK et al. (2002) Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51:2796–2803CrossRefPubMed Buchanan TA, Xiang AH, Peters RK et al. (2002) Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51:2796–2803CrossRefPubMed
7.
go back to reference Margolis KL, Bonds DE, Rodabough RJ et al. (2004) Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: Results from the Women’s Health Initiative Hormone Trial. Diabetologia 47: dx.doi.org/10.1007/s00125-004-1448-xCrossRef Margolis KL, Bonds DE, Rodabough RJ et al. (2004) Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: Results from the Women’s Health Initiative Hormone Trial. Diabetologia 47: dx.doi.org/10.1007/s00125-004-1448-xCrossRef
8.
go back to reference Kanaya A, Herrington D, Vittinghoff E et al. (2003) Glycemic effects of postmenopausal hormone therapy: the heart and estrogen/progestin replacement study. Ann Intern Med 138:1–9CrossRefPubMed Kanaya A, Herrington D, Vittinghoff E et al. (2003) Glycemic effects of postmenopausal hormone therapy: the heart and estrogen/progestin replacement study. Ann Intern Med 138:1–9CrossRefPubMed
9.
go back to reference Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419CrossRefPubMed Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419CrossRefPubMed
10.
go back to reference Kim C, Seidel KW, Begier EA, Kwok YS (2001) Diabetes and depot medroxyprogesterone contraception in Navajo women. Arch Intern Med 161:1766–1771CrossRefPubMed Kim C, Seidel KW, Begier EA, Kwok YS (2001) Diabetes and depot medroxyprogesterone contraception in Navajo women. Arch Intern Med 161:1766–1771CrossRefPubMed
11.
go back to reference Anderson GL, Limacher M, Assaf AR et al. (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291:1701–1712CrossRefPubMed Anderson GL, Limacher M, Assaf AR et al. (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291:1701–1712CrossRefPubMed
12.
go back to reference Andersson B, Mattsson LA, Hahn L et al. (1997) Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:638–643PubMed Andersson B, Mattsson LA, Hahn L et al. (1997) Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:638–643PubMed
13.
go back to reference Andersson B, Johannsson G, Holm G et al. (2002) Raloxifene does not affect insulin sensitivity or glycemic control in postmenopausal women with type 2 diabetes mellitus: a randomized clinical trial. J Clin Endocrinol Metab 87:122–128CrossRefPubMed Andersson B, Johannsson G, Holm G et al. (2002) Raloxifene does not affect insulin sensitivity or glycemic control in postmenopausal women with type 2 diabetes mellitus: a randomized clinical trial. J Clin Endocrinol Metab 87:122–128CrossRefPubMed
14.
go back to reference Tuomilehto J, Lindstrom J, Eriksson JG et al. (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350CrossRefPubMed Tuomilehto J, Lindstrom J, Eriksson JG et al. (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350CrossRefPubMed
Metadata
Title
Does WHI tell us how to prevent diabetes?
Author
E. R. Seaquist
Publication date
01-07-2004
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 7/2004
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-004-1449-9

Other articles of this Issue 7/2004

Diabetologia 7/2004 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.